Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial Article

Mehta, MP, Gervais, R, Chabot, P et al. (2006). Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial . JOURNAL OF CLINICAL ONCOLOGY, 24(18_suppl), 7014-7014. 10.1200/jco.2006.24.18_suppl.7014

cited authors

  • Mehta, MP; Gervais, R; Chabot, P; Shapiro, WR; Patchell, RA; Glantz, MJ; Recht, L; Phan, S; Smith, JA; Renschler, MF

authors

publication date

  • June 20, 2006

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • 6 Evaluation of treatments and therapeutic interventions
  • 6.1 Pharmaceuticals
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Neurosciences

Digital Object Identifier (DOI)

publisher

  • American Society of Clinical Oncology (ASCO)

start page

  • 7014

end page

  • 7014

volume

  • 24

issue

  • 18_suppl